Abstract. Prostaglandins support progression of colorectal cancer by several mechanisms. This conclusion is based on epidemiological and drug intervention long-term studies or retrieved from animal and cell culture experiments. The aim of the present study was to map receptor and enzyme expression for prostanoid metabolism in the presence of high or low PGE 2 content within colon cancer tissue at primary tumor operation and after short-term preoperative provision of non-steroidal anti-inflammatory drug (NSAID). Twentythree unselected patients with colon cancer were randomly selected to receive indomethacin (NSAID) or sham treatment for 3 days before surgery. Normal colon and tumor tissue were collected at operation for RNA extraction. Tissue PGE 2 levels were measured by radioimmunoassay. Gene expression was quantified by microarray and real-time PCR. COX-1 expression increased proportionally to COX-2 expression in colon cancer tissue from untreated patients. Indomethacin reduced PGE 2 content in normal and tumor tissue with subsequently decreased IP, HPGD and PPARÁ receptor expression in both tumor and normal colon tissue, while subtype EP 1-4 receptors were not significantly influenced by indomethacin treatment. MPGES-1 expression was not related to overall PGE 2 content in tumor and colon tissue, but decreased significantly in normal tissue during indomethacin exposure. Reduction of tumor tissue PGE 2 was related to significant alteration in expression of several hundred genes indicating decreased cell cycling and increased apoptosis during indomethacin treatment, probably related to upregulation of acute phase reactants in tumor tissue. Increased prostanoid activity in colon cancer tissue is related to cross-talk between tumor and stroma cells.
Introduction
Cyclooxygenase (COX) inhibition is linked to chemoprevention of colorectal cancer in part based on effects to attenuate tumor growth (1, 2) . Our previous investigations have indicated that expression of COX-2 and subtype EP 2 receptors in colorectal cancer tissue predict patient survival following intended curative operation (3) . Thus, prostaglandins are involved in different metabolic pathways assumed to support tumor progression by alterations in cell proliferation, adhesion, migration, differentiation, apoptosis and angiogenesis (1, 2, (4) (5) (6) (7) (8) (9) (10) (11) . The main function of NSAIDs is reversible inhibition of COX enzymes, where COX-1 is constitutively expressed in most tissues, while COX-2 is usually induced by growth factors and cytokines (12) . A variety of such promoters induce COX-2 and PGE 2 synthase (mPGES-1) in tumor tissue (13, 14) . Thus, cyclooxygenases are key enzymes in prostaglandin biosynthesis for conversion of arachidonic acid to the prostaglandin (PG) precursor PGH 2 , which is immediately converted to different prostaglandins (PGH 2 , PGE 2 , PGH 2· , PGI 2 /prostacyclin or TXA 2 ) depending on various cellular enzyme synthases (15) . Net effects of COX enzymes in tumor tissue and cells depend on the balance between produced prostaglandins and interactions with corresponding receptors (3, 11, (16) (17) (18) . Enzymes catalyzing degradation of prostaglandins as 15-hydroxyprostaglandin dehydrogenase (HPGD) should also be of importance for overall tissue levels of PGE 2 (19) , although less evaluated in relationship to tumor progression (12) . Thus, short-term COX-inhibition by provision of preoperative NSAID treatment of patients with colorectal cancer should offer a means to evaluate relationships between prostanoid production and the expression of corresponding receptors and other genes dependent on high PGE 2 in colon cancer tissue.
Patients and methods
Patients. Patients were randomized between 1998 and 2004 to receive NSAID or sham-treatment for 3 days before primary surgery for colorectal cancer as described elsewhere (20) . NSAID treatment was indomethacin (Confortid, 50 mg x 2, Alpharma, n=9) during three preoperative days together with proton pump inhibitor as prophylaxis (Nexium 40 mg daily, Astra Zeneca), which was also provided as shamtreatment to control patients (n=14). None of our patients received radiochemotherapy pre-or post-operatively according to standard criteria at our institution and individual review of patient study at the time of operation. The group of patients consisted of 43% males and 57% females with a median age of 77 years (range 56-85 years) at surgery. Their median survival was 11 months (range 6-55 months) following surgery according to a recent update of survival (June 2008) with 12 patients still alive. Tumors were histologically classified as Dukes A (4), Dukes B (9) and Dukes C (10) corresponding to stage I-III respectively. All patients with Dukes A stage were alive 2008.
Tumor tissue material. Tumor and normal large bowel tissue samples were collected down to the serosa level and kept fresh frozen in liquid nitrogen and stored in -80˚C until analysis at primary operation. Certified pathologists staged all tumors. Tumor samples contained around 70-80% tumor cells based on visual inspection.
Cell culture. Two well-differentiated human colorectal carcinoma cells lines were used (HT-29 and HCA-7 SigmaAldrich (St. Louis, MO, USA). Cells were cultured in McCoy's 5A medium (Fisher Scientific, Sweden) supplemented with 1.5% fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml streptomycin and 292 μg/ml L-glutamine (Bergman Labora, Sweden) and were maintained as monolayer in cell culture vials from Sigma-Aldrich in a humidified (98%) incubator at 37˚C with 5% CO 2 with a medium change once weekly. Indomethacin (Confortid, Alpharma ApS, Langenfeld, Germany) was diluted from a stock solution of 5 mg/ml and added to final concentration of 8.4 μM in cell culture medium of study cells whereas control cells were provided saline of the same amount. Microarray expression profiling. Tumor mRNA from 6 indomethacin-treated patients and from 6 control patients were pooled respectively with 2 males and 4 females in each group [indo, 71±11 (SD) years; ctrl, 74±5 (SD) years]. Dukes staging in each group were A (1), B (2) and C (3). From indomethacin treated patients 400 ng of tumor mRNA were labeled with Cy-3-dCTP (Amersham Biosciences) in a cDNA synthesis reaction with Agilent Fluorescent Direct Label, tumor mRNA from control patients (400 ng) was labeled with Cy-5-dCTP. Similar principles were used for normal colon tissue and HCA-7 cells. Pooled tumor cDNA from 6 indomethacin treated patients versus pooled tumor cDNA from 6 sham treated patients were hybridized on whole human oligo microarrays. The expression array (Whole Human Genome Oligo Microarray, Agilent Technologies) contained 44290 features including positive and negative control spots. Hybridization was performed during 18 h with test versus control cDNA in a dual-color experiment followed by post-hybridization washes according to in situ instructions (Hybridization Kit Plus, Agilent Technologies). Microarrays were dried with nitrogen gas in a laminar flow bench and images were quantified on Agilent G2565 AA microarray scanner. Fluorescence intensities were extracted using Feature Extraction 9.1 software program (Agilent Technologies). Dye-normalized, outlier-and background subtracted values were analyzed in GeneSpring (GX7.3.1) software program imported with the enhanced FE Agilent import. Two technical replicates of tumor tissue versus normal colon tissue were run. Hands-on-variation was checked in a Table I . Prostanoid receptor and enzyme expression in colorectal cancer and corresponding normal colon tissue in patients treated by indomethacin for 3 days preoperatively compared to untreated controls. 
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a Comparative C T -method, 2-ΔΔCT , TaqMan 7700, Applied Biosystems. b Relative standard curve, LightCycler, Roche
Diagnostics. c 15-deoxy-Δ12,14-PGJ 2 , a hydration break-down product of PGD 2 .
- Statistical analyses. Results are presented as mean ±SEM in tables and figures. Patients were randomized by a computer based algorithm to receive indomethacin, accounting for age, sex and tumor stage, which made indomethacin and sham treated patients comparable in these respects and explains the uneven number between study and control groups (21) . Power estimates (·<0.05, ß=0.80) indicated that around 10 patients in each group would be enough to quantify significantly altered gene expression by real-time and qPCR according to our earlier experience (3). Statistical testing was performed by non-parametric tests (Mann-Whitney) p<0.05 was regarded statistically significant and p<0.10 a trend to significance in two-sided tests. This study protocol was approved by the board of ethics at University of Gothenburg (NCT00473980).
Results
Overall PGE 2 production was 4.87±2.9 μg/g in tumor tissue and 0.32±0.18 μg/g in normal colon tissue from indomethacin treated patients (p<0.20), while untreated control patients displayed 34.4±11.1 μg/g in tumor tissue and 6.11±2.6 μg/g in normal colon tissue (p<0.01). Thus, indomethacin treatment decreased PGE 2 content significantly in both tumor tissue (p<0.008) and normal colon tissue (p<0.01). Overall, gene expression appeared higher in normal colon tissue compared to tumor tissue (Tables I and IV) .
Gene expression and indomethacin treatment. Pre-operative indomethacin treatment for 3 days increased tumor tissue mPGES-1 expression, while IP, PPARÁ and HPGD expression were decreased compared to tumor tissue from control patients. Indomethacin treatment increased expression of DP1, DP2 and mPGES-1 in normal colon tissue, whereas expression of IP, TP, HPGD and PPARÁ receptors were significantly decreased (Table I) .
Array profiling analysis, filtered with a 3-fold change (p<0.01), displayed 281 genes with altered expression during indomethacin treatment (72 up-regulated and 209 downregulated; p<0.05) (Table II) . Gene pathways for tumor progression indicated that 30 genes were affected related to apoptosis while 60 significantly altered genes were related to proliferation. Similar conclusions appeared when expression data were incorporated into cell-algorithms defined by the Gene Spring computer program (KEGG components) indicating that apoptosis and cell cycle activities were significantly affected, where down-regulation of cell survival factors appeared to promote balance towards apoptosis and withdrawal of external growth factors seemed to decrease activation through glycogen synthase 3ß kinase (not shown). Indomethacin also affected significantly IL3 (CSF2RB ↓, CISH ↓, BCL2L11 ↓) and IL7 pathways (BCL2L11 ↓, IRS2 ↓) (not shown). Top 10 up-regulated genes involved mainly markers for acute phase reactants and immune response as reported (20) , while top 10 most down-regulated genes had mainly undefined functions (Table III) .
Endogenous PGE 2 and prostanoid receptor expression. Shamtreated control patients were divided into two groups based on high (n=6) and low (n=5) PGE 2 concentration in tumor tissue (p<0.01). Receptor and enzyme expression were not related to overall high or low PGE 2 content in tumor tissue, Table II . Number of significantly up-(↑) and down-(↓) regulated genes in colorectal tumor tissue and in cultured tumor cells (HCA-7) treated with indomethacin as described in Materials and methods. ----------------------------------------------------------------------------------------------------- a Tumor tissue (in vivo) and tumor cells (in vitro) were exposed to indomethacin (3 days, 14 days) and hybridized to unexposed control specimens.
-----------------------------------------------------------------------------------------------------
but expression of EP 3 (p<0.07), EP 4 (p<0.02) and TP (p<0.03) were significantly altered in normal colon tissue accounting for low PGE 2 content (Table IV) . COX-1 expression was highly related to COX-2 expression in tumor tissue (Fig. 1) . This was explained by a proportional increase of COX-1 in tumors with high COX-2, while there was no correlation between COX-1 and COX-2 expression in tumors with low COX-2 expression (not shown).
Effects of indomethacin on cultured tumor cells.
Indomethacin treatment during 14-days of cultured cells reduced production and medium levels of PGE 2 in HCA-7 cells (indomethacin treated <2.5 pg/ml; control cells 125 pg/ml medium) while HT-29 cells remained low in PGE 2 production with or without indomethacin (<2.5 pg/ml). Effects of constant indomethacin exposure to HCA-7 cells on EP receptors and COX enzyme Table III . Expression of 10 most up-and down-regulated genes in colorectal tumor tissue from indomethacin-treated patients compared to untreated controls. 
-----------------------------------------------------------------------------------------------------Gene name Gene symbol FC Protein function (GeneID) -----------------------------------------------------------------------------------------------------

interaction -----------------------------------------------------------------------------------------------------FC is fold change alteration in expression.
a Reported elsewhere (20) . Figure 1 . The relationship between COX-1 and COX-2 expression in colon cancer tissue from untreated patients. Table IV . Prostanoid receptor and enzymes expression in colorectal cancer and corresponding normal colon tissue from selected patients with PGE 2 levels above (high) or below (low) the median value in tumor tissue from untreated controls (p<0.01).
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- Diagnostics. c 15-deoxy-Δ12,14-PGJ 2 , a hydration break-down product of PGD 2 .
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expression were negligible compared to culture time whereas COX-2, HPGD and EP1 subtype receptor expression displayed alterations related to altered PGE 2 exposure (Fig. 2) . Unexpectedly, expression of HPGD was overall higher in the presence of indomethacin compared to untreated cells. Also, alterations in up-regulation of genes appeared more frequent in cultured cells compared to findings in tumor tissue during indomethacin exposure (Table II) .
Discussion
Animal experiments and clinical investigations have provided a large body of information on the role of prostanoid influence in carcinogenesis and progression of colorectal cancer, although precise mechanisms are not understood (12) . In this context earlier studies in our laboratory have relied on effects by indomethacin to inhibit cyclooxygenase activity in tumor and host cells, although it is likely that prostaglandin independent pathways occur and that COX-2 inhibitors may have different overall effects compared to mixed COX-1/ COX-2 inhibition (1,2,22,23). Our previous studies have indicated that indomethacin attenuates whole body systemic inflammation, which may lead to prolonged survival in patients with systemic cancer (24) . Tumor-host interactions at both systemic and local tumor levels are nowadays comparatively well understood representing complex networks of signaling between tumor cells and surrounding stroma including inflammatory and endothelial cells (25) . Numerous studies have shown that prostanoids, particularly PGE 2 , are second messengers in both cell to cell communication and involve intracellular reactions related to Gcoupled protein receptors. It is thus evident that systemic reactions such as progressive weight loss, anorexia and systemic inflammation relate to prostaglandin activities in various organs including tumor tissue (26) . Therefore, it should be possible to specifically attenuate local and systemic progressive disease by understanding ligand receptor activities in prostanoid related metabolism and subsequently confirm main signaling pathways (12, 23, 27) . In this context it is important to emphasize that up-regulation of COX-2 expression in tumor tissue is usually not a general phenomenon among tumor cells (3, 28) . Indeed, it is a scattered cellular phenomenon within colon cancer tumors showing 'hot spots' of COX-2 expression (28), reflected by overall lower content of transcripts for prostanoid related proteins in tumor tissue compared to normal colon tissue (3); contrary to findings in cell cultures of colon cancer (29) . Therefore, it is most likely that upregulation of COX-2 in some tumor cells explains the majority of increased PGE 2 content in tumor tissue beside its decreased degradation, although this assumption has not yet been directly confirmed in clinical specimens. However, tumor stroma cells also express considerable amounts of COX-2 for PGE 2 synthesis in colorectal tumor tissue (28) . Accordingly, we have reported that both COX-1 and COX-2 protein correlate to PGE 2 content in colon cancer tissue (28) . The present results demonstrate that COX-1 expression was proportionally increased to COX-2 expression in colon cancer tissue. This fact explains why unspecific cyclooxygenase inhibitors attenuate tumor progression effectively (2, 20, 24) . It has also been reported that mPGES-1 is over-expressed in colorectal cancer responsible for PGE 2 production (14), although increased PGE 2 levels in tissue may as well depend on PGE 2 break-down by HPGD. Accordingly, HPGD expression was low in tumor tissue from our present patients when compared to overall levels in their normal colon tissue. HPGD was also significantly decreased in response to indomethacin treatment in vivo, but showed unexpectedly an opposite response in cultured colon cancer cells (Fig. 2) . Prostanoid receptor expressions were to some extent affected by indomethacin treatment with reduced IP receptor expression in both tumor and normal colon tissue. IP is activated by prostacyclin (PGI 2 ) and has been reported to inhibit apoptosis in colonic epithelial cells (30, 31) . Receptors for PGD 2 (DP1 and DP2) showed increased expression in normal colon tissue during indomethacin treatment with evidence that indomethacin may have direct agonistic effect on DP2 receptor (32) . Interestingly, PGD 2 may have several effects in tumor tissue as decreased proliferation including pro-and anti-inflammatory actions with significant effects on immune reactions (33) (34) (35) (36) . Thus, different effects within a tumor compartment are likely dependent on the type of PGD 2 receptor activation (DP1, DP2 and PPARÁ). PPARÁ is usually recognized as a tumor suppressor (37), but indomethacin decreased its expression in both normal and tumor tissue (Table I) . Also, expression of EP 3 , EP 4 and TP in normal colon tissue were significantly related to net PGE 2 production, but not so in tumor tissue.
We also investigated receptor and enzyme expression (subtype EP [1] [2] [3] [4] , COX-1, COX-2, HPGD) in cultured colon cancer cells (HCA-7) in the presence of indomethacin, since PGE 2 is regarded a major prostaglandin produced by tumor cells (2) . Specific effects by indomethacin on EP receptor expression were not apparent except for EP 1 . However, indomethacin decreased temporarily expression of COX-2 and increased expression of HPGD in cultured tumor cells, but decreased HPGD expression in tumor tissue in vivo in contrast to present and previous information in cultured cells (38) . Findings of enhanced HPGD activity and content have been observed in human medullary thyroid cancer and tumor C cells during indomethacin treatment (39, 40) . Thus, discrepant results on HPGD expression in vitro and in vivo during indomethacin exposure emphasize difficulties to compare results from in vivo mixed tissues with findings in isolated cell cultures. This may illustrate limitation for interpretations of in vivo observations, but represents also the strength to reflect net effects among various cells in complexed tumor tissue; for example that tumor tissue expression of COX-2 and EP 2 receptors predicted survival without being overall increased in tumor tissue (3), a phenomenon that emphasizes the role of stroma cells for tumor prostanoid metabolism.
Preoperative treatment with indomethacin for 3 days caused alterations in expression of numerous genes with different functions, assessed on pooled RNA from Dukes A-C tumors. Our purpose with gene profiling was to map appearance/disappearance of gene transcripts in relationship to high and low PGE 2 content in tumor tissue despite tumor stage, as earlier reported for normal colon tissue after longterm treatment with celecoxib (41) . Similarly, an earlier report from our group displayed impacts on HLA antigen expression including markers for immune defense reactions (20) , in agreement with a report by Auman et al who pretreated patients with celecoxib for 7 days and found evidence of increased immune response (42) . Such results are present among listed top ten up-regulated genes, which seemed to be related in general to promotion of acute phase and immune reactions (Table III) . However, melanoma inhibitory activity (MIA) was upregulated by indomethacin. Expression of MIA is an early event in melanoma development and correlates with tumor progression and tumor invasiveness secondary to cell-matrix interactions (43) . The role of MIA and its eventual role in immune interactions within colorectal tumor tissue remains to be elucidated. Others have reported that MIA is highly expressed in pancreatic carcinoma compared to normal pancreas (44) . However, the seemingly negative appearance of MIA from low tissue levels in colon cancer during NSAID treatment is obviously cancelled out in some respect (8, 20, 24) . We can also provide information on alterations in gene expression and net PGE 2 production in tumor tissue affecting pronounced alterations in apoptosis (LGALS2), differentiation (RARRES1) and regulation of energy metabolism (AKAP14, MT1E) in agreement with findings occurring in animal tumor models (45) . Gene algorithm analysis suggested apoptosis as the clearly affected pathway in tumor tissue in the present patients, which agrees with overall findings in tumor tissue in cell culture experiments (29) . Seen together, our computer based algorithm analyses indicated that extrinsic 'survival factors' were particularly down-regulated to promote net apoptosis, together with decreased external growth factor exposure for stimulation of cell cycling (24) . A speculative suggestion is that stroma cells are influenced to decrease external stimulation of tumor cells and promote apoptosis during cyclooxygenase inhibition (28) .
In conclusion, the present clinical findings emphasized that prostanoid metabolism is complex in colon cancer tissue and involves several hundred genes, which appear to control local tumor growth and net immune response (20, 42) , cell proliferation, differentiation, energy metabolism and apoptosis as earlier reported for normal colon tissue (41) . However, alterations in tumor tissue gene expression following indomethacin treatment were not entirely similar to alterations in normal colon tissue from the same patients or to findings in cultured colon cancer cell lines. This and other phenomena point to the importance of stroma cells (28) . A detailed understanding of the cross-talk between stroma and tumor cells and the signaling pathways behind altered net PGE 2 production in colon cancer tissue may represent future targets for attenuation of local tumor growth.
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